Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]Ga-DOTA-STR-17126 is a gallium-68 labeled radiopharmaceutical designed for positron emission tomography (PET) imaging of tumors expressing the gastrin-releasing peptide receptor (GRPR). It consists of a GRPR-targeting peptide (STR-17126) conjugated to the chelator DOTA, which complexates the radioisotope gallium-68. GRPR is frequently overexpressed in various cancers, including prostate and breast cancer, making it a valuable target for molecular imaging. This agent is part of a theranostic pair, where its lutetium-177 labeled counterpart, [177Lu]Lu-DOTA-STR-17126, is used for targeted radionuclide therapy and dosimetry. It is currently being evaluated in Phase 0 clinical trials by the Integrated Haematology and Oncology Network in Australia for the detection and management of advanced or metastatic cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [68Ga]Ga-DOTA-STR-17126.